Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. President and CEO Charles K. Janac, through Bayview Legacy, LLC, reported open-market sales of 40,000 shares of Arteris common stock on March 25–26, 2026 at weighted average prices of $18.0309 and $18.3458. These trades were executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following the transactions, Bayview Legacy, LLC holds 9,189,071 shares indirectly, while separate holding entries show Janac with 217,538 shares held directly and 56,252 shares held through the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported selling a total of 40,000 shares of Arteris common stock in two open-market transactions. On March 25, it sold 7,012 shares at a weighted average price of about $18.03 per share, followed by 32,988 shares on March 26 at a weighted average price of about $18.35 per share.
The sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC indirectly holds 9,189,071 Arteris common shares, so the sale represents a small portion of its overall position.
AIP (Form 144): Notice to sell 20,000 shares of Common Stock. The filing lists a proposed sale of 20,000 common shares with an aggregate reported value of $359,800.00. The cover row references Morgan Stanley Smith Barney LLC Executive Financial Services and the listing 03/26/2026.
The excerpt also lists multiple recent 10b5-1 sales by BAYVIEW LEGACY, LLC and one sale by K. CHARLES JANAC across January–March 2026, showing executed transactions and proceeds for context.
AIP reported a proposed sale of 20,000 shares of Common Stock. The filing excerpt lists multiple 10b5-1 sales by BAYVIEW LEGACY, LLC on 01/08/2026, 01/15/2026, 02/09/2026, 03/09/2026, and others, with trade sizes such as 50,000 shares on 01/08/2026 and 41,000 shares on 03/09/2026. The excerpt also shows a 10b5-1 sale by K. CHARLES JANAC for 11,145 shares on 01/06/2026. Broker information lists Morgan Stanley Smith Barney LLC and a filing date of 03/25/2026.
Arteris, Inc. President and CEO Charles K. Janac reported open-market sales of a total of 50,000 shares of common stock through Bayview Legacy, LLC on March 9–10, 2026. The shares were sold at weighted average prices of $14.2104 and $14.663 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After the sales, indirect holdings through Bayview Legacy, LLC were 9,229,071 shares, in addition to 217,538 shares held directly and 56,252 shares held via the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of a total of 50,000 shares of common stock over two days. On March 9, 2026, it sold 41,000 shares at a weighted average price of $14.2104 per share, and on March 10, 2026 it sold 9,000 shares at a weighted average price of $14.6630. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted by K. Charles Janac as manager of Bayview Legacy, LLC. Following the transactions, Bayview Legacy, LLC held 9,229,071 Arteris common shares indirectly.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for the proposed resale of 20,000 Common shares related to an Nasdaq‑traded issuer, dated 03/09/2026.
The filing lists recent 10b5-1 brokered sales by related holders in the prior three months, including sales by BAYVIEW LEGACY, LLC of 50,000 shares on 01/08/2026 (proceeds $829,155.00) and 47,244 shares on 02/09/2026 (proceeds $718,359.19).
Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of 109,721 shares of common stock by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust. The trust sold 106,031 shares on March 2, 2026 at a weighted average price of $17.2127 and 3,690 shares on March 4, 2026 at a weighted average price of $17.0153, under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, the trust held 390,000 shares indirectly, and Raza also held 20,839 shares directly.
AIP reported sale notices and related 10b5-1 transactions. The filing lists an issuer notice to sell 90,000 common shares from previously exercised stock options dated 12/28/2020, and discloses 10b5-1 sales of common shares on 02/25/2026, 02/26/2026, and 02/27/2026.
The excerpt shows executed 10b5-1 trades of 4,907, 73,610, and 11,762 common shares (totaling 90,279 shares) with reported proceeds in dollars. Shares outstanding are listed as 45,467,261 as of 03/02/2026.
Arteris, Inc. director-related entity activity shows the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust selling a total of 90,279 shares of common stock in open-market transactions. These sales occurred on February 25–27, 2026 at weighted average prices around $17 per share under a pre-arranged Rule 10b5-1 trading plan.
After these indirect sales, the trust held 499,721 shares, while a separate direct holding for the reporting person stood at 20,839 shares of Arteris common stock as of February 25, 2026.